Business Wire16h
Corstasis Therapeutics to Present Pivotal Trial Data on Novel Bumetanide Nasal Spray at American Heart Association Scientific Sessions 2024
Corstasis to present pivotal trial data on Bumetanide Nasal Spray at AHA 2024, highlighting safety, and efficacy. #AHA2024. Home is where the heart is ...
'We are very hopeful' | New nasal spray could delay Alzheimer's by years, researchers say
Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling ...
Scientists Develop Breakthrough Nasal Spray That Could Delay Alzheimer’s by Over a Decade
Research from the College of Medicine provides promising insights into delaying the progression of Alzheimer’s disease for ...
Nasal Spray Could Delay Alzheimer's by Years
Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at Texas A&M University College of Medicine. Alzheimer's is the most common form of ...
Hosted on MSN4d
ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m
ALK-Abelló has acquired rights to Neffy adrenaline nasal spray in Europe and Canada, amongst other countries, from ARS ...
Business Insider6d
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)
The agreement grants ALK exclusive global rights to the neffy ® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key ...